Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2025-08-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于新天地药业股份有限公司使用部分超募资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsoring institution (华泰联合证券有限责任公司) regarding the use of part of the over-raised funds by 新天地药业股份有限公司 to permanently supplement working capital. It includes references to regulatory rules, approvals by various company committees (audit committee, independent directors, board of directors, supervisory board), and the need for shareholder approval. The document is not a financial report itself but a formal opinion or verification related to the use of funds raised in an IPO. It does not contain financial statements or earnings data but focuses on compliance and procedural approvals. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance and verification document rather than a financial report or announcement of voting results.
2025-08-11 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 新天地药业股份有限公司 regarding the approval of the 2025 semi-annual report and related financial matters. It references the 2025 semi-annual report and other related reports but does not contain the actual financial statements or detailed financial data itself. Instead, it states that the detailed reports are disclosed elsewhere (on the cninfo website). The document is short (1930 characters) and primarily serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a formal announcement related to regulatory compliance and corporate governance but not the full interim report or financial statements.
2025-08-11 Chinese
关于召开2025年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2025 second extraordinary general meeting of shareholders for 新天地药业股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda proposals, and instructions for shareholders. There is no financial data or report content; rather, it is an announcement informing shareholders about the meeting logistics and voting process. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2025-08-11 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also includes shareholder information and company basic data. The length of the document is 9873 characters, which is substantial and contains actual financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-11 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from a company named 新天地药业股份有限公司. It details the decisions made at the sixth board's seventh meeting, including approval of the 2025 semi-annual report and related financial and fundraising reports. The document references that the actual 2025 semi-annual report and other detailed reports are disclosed separately on an external website (巨潮资讯网). The text itself does not contain the full semi-annual report or detailed financial statements but rather announces the board's approval of these reports and other resolutions. The document length is short (2017 characters), and it serves as an official announcement of board meeting resolutions and approvals, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and board meeting resolution notice, rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2025-08-11 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug information, approval, and impact on the company. The document is short (2292 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-07-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.